Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moti Ramgopal

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|May 10, 2016
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant WomenMoti Ramgopal, Olayemi Osiyemi, Carmen Zorrilla, et al.
AIDS Research and Therapy|September 27, 2025
Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort studyPaul E Sax, Janna Radtchenko, Megan Dunbar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2024
DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight GainDavid Anderson, Moti Ramgopal, Debbie P Hagins, et al.
HIV Medicine|October 6, 2024
Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysisJoseph J Eron, Moti Ramgopal, Olayemi Osiyemi, et al.
Medicine|February 24, 2025
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority studyIndira Brar, Peter J Ruane, Mezgebe Berhe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2019
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND StudyGregory D Huhn, Gordon Crofoot, Moti Ramgopal, et al.
Human Vaccines & Immunotherapeutics|July 11, 2019
Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B virusesMichael A Carlock, John G Ingram, Emily F Clutter, et al.
Blood|April 17, 2013
Interleukin-7 promotes HIV persistence during antiretroviral therapyClaire Vandergeeten, Rémi Fromentin, Sandrina DaFonseca, et al.
HIV Research & Clinical Practice|September 20, 2019
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 studyMiranda Murray, Federico Pulido, Anthony Mills, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b studySamit R Joshi, Mar Masiá, Essack Mitha, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Journal of Acquired Immune Deficiency Syndromes (1999)|May 10, 2016
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant WomenMoti Ramgopal, Olayemi Osiyemi, Carmen Zorrilla, et al.
AIDS Research and Therapy|September 27, 2025
Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort studyPaul E Sax, Janna Radtchenko, Megan Dunbar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2024
DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight GainDavid Anderson, Moti Ramgopal, Debbie P Hagins, et al.
HIV Medicine|October 6, 2024
Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysisJoseph J Eron, Moti Ramgopal, Olayemi Osiyemi, et al.
Medicine|February 24, 2025
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority studyIndira Brar, Peter J Ruane, Mezgebe Berhe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2019
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND StudyGregory D Huhn, Gordon Crofoot, Moti Ramgopal, et al.
Human Vaccines & Immunotherapeutics|July 11, 2019
Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B virusesMichael A Carlock, John G Ingram, Emily F Clutter, et al.
Blood|April 17, 2013
Interleukin-7 promotes HIV persistence during antiretroviral therapyClaire Vandergeeten, Rémi Fromentin, Sandrina DaFonseca, et al.
HIV Research & Clinical Practice|September 20, 2019
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 studyMiranda Murray, Federico Pulido, Anthony Mills, et al.
Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b studySamit R Joshi, Mar Masiá, Essack Mitha, et al.
Pageof 6